HOME JOURNALS CONTACT

Pakistan Journal of Biological Sciences

Year: 2006 | Volume: 9 | Issue: 4 | Page No.: 632-635
DOI: 10.3923/pjbs.2006.632.635
The Preventive Effect of Sacharomyces boulardii in Pathogenesis of Salmonella typhimurium in Experimentally Infected Rats
M. Mahzounieh, I. Karimi , T. Zahraei Salehi and R. Marjanian

Abstract: The present research studied the capacity of Saccharomyces boulardii (S. boulardii) to antagonize Salmonella typhimurium (S. typhimurium) in the intestinal tract and humoral response of rats after challenging with S. typhimurium. Sixty conventional male rats were divided at random into 4 groups. The S.boulardii suspensions contained 106, 07 and 108 cells mL-1 were administered (orally) to 3 groups (A, B and C) of rats, respectively for 5 continues days. The rats of group D received Saline instead of S.boulardii and used as control. All of rats challenged with 107 CFU of pathogenic S. typhimurium at fifth day. The viable Salmonella were counted at g-1 of faeces of rates at 0, , 3, 5 and 7 days after challenge. Titer of anti- salmonella antibodies were determined. Present experiments showed that S. boulardii could reduce the bacterial colonization in experimental animals. There was a significant reduction at number of S. typhimurium between control and test groups. A daily dose of 106 yeast cells was resulted in the most reduction in bacterial shedding and high titers of anti salmonella antibodies. The mortality rates were 0 and 46.4% in yeast treatment and control animals, respectively. S. typhimurium viable cells were not detected in the organs of yeast-treated rats. We conclude that S. boulardii has a preventive effect in pathogenesis of S. typhimurium.

Fulltext PDF Fulltext HTML

How to cite this article
M. Mahzounieh, I. Karimi , T. Zahraei Salehi and R. Marjanian , 2006. The Preventive Effect of Sacharomyces boulardii in Pathogenesis of Salmonella typhimurium in Experimentally Infected Rats. Pakistan Journal of Biological Sciences, 9: 632-635.

Keywords: pathogenesis, rat, Saccharomyces boulardii, Salmonella typhimurium and probiotic

INTRODUCTION

Diarrhoea caused by infectious agents is responsible for large economic losses in animal production. One of the most frequent genus of bacterial contaminants of domestic animals is Salmonella. Especially, in the case of Salmonella infections, these may be asymptomatic and production losses are insignificant. However, colonized food animals can serve as a source of infection for humans causing a disturbance of the gastrointestinal microbiota. Antibiotics have traditionally been the most frequently administered agents to counteract this type of infections. However, the current trend is to totally eliminate the prophylactic use of antibiotics in farming. The use of several antibiotics has already been banned. Therefore, in an effort to prevent or cure these disorders, alternative forms of therapy are searched. have been suggested as alternative therapies for the treatment or prevention of gastroenteritis (Laukova et al., 2004).

The yeast of Saccharomyces boulardii, has originally been isolated from lychee fruit in Indochina and used first in France to treat diarrhoea, beginning in the 1950s (McFarland and Bernasconi, 1993). S.boulardii is effective in the prevention and treatment of many forms of diarrhoea in humans, especially antibiotic-associated diarrhoea and colitis. Recent studies showed that S. boulardii administration significantly reduced the frequency of diarrhoea in patients administered antibiotic therapy and that in combination with vancomycin or metronidazole. It reduced the number of relapses of C. difficile infection (Castagliuolo et al., 1999). Although, S. boulardii is not a constituent of the normal gut flora, it survives undigested in the lower gastrointestinal tract after oral administration and can be retrieved from faeces (Roffe, 1996). Besides of preventive and therapeutic effects, Gil de los Santos et al. (2005) showed that this probiotic improved feed efficiency in broilers. Agawane and Lonkar (2004) found that use of S. boulardii in field conditions could reduce the adverse effect and economic losses of ochratoxicosis in broilers.

This study was conducted to determine the influence of the yeast on salmonella population as well as their inhibitory effect in pathogenic action of salmonella in rat after oral administration.

MATERIALS AND METHODS

The present research work has conducted at department of pathobiology, Shahrekord University, Shahrekord, Iran, in 2004. The yeast, S. boulardii was cultured on Sabouraud-dextrose Agar medium (Merck) at pH 6 and was incubated at 30°C for 48 h. At the end of fermentation, yeasts were recovered and suspended in a sterile aqueous solution of 0.05 M NaCl isotonic. We prepared 3 suspension (A, B and C) contained 106, 107 and 108 cells per mL and stored them at 4°C for 5 days.

A clinical isolate of S. typhimurium was selected for resistance to tetracycline by successive cultures on MacConkey agar (Biolife) containing 65 μg tetracycline mL-1 medium. Strain cultures in brain heart infusion (BHI-Difco) incubated at 37°C for 18 h were used as inocula. All groups received 107 Colony Forming Units (CFU) of S. typhimurium. The number of CFU in the inocula and in the feces was determined by plating 0.1 mL of the suspensions and of their respective decimals dilutions onto sterile normal saline, in MacConkey agar supplemented with 65 μg tetracycline mL-1 (Andreatti Filho et al., 2000). The rats were challenged by intraesophageal inoculation of 1 mL of the bacterial suspension.

Sixty conventional male rats who didn’t shedding non-lactose fermenting bacteria, weighting 200±20 g divided into 4 groups (A, B, C and D). Throughout the study period, each rat was placed in an individual decontaminated cage in a controlled heat environment with free access to unmedicated commercial feed and water.

Rats in 3 groups (A, B and C) received S.boulardii suspensions as a single daily dose contained 106,107 and 108 cells per ml (orally) from day 1 to 5, respectively. The rats of group D received saline instead of S. boulardii and used for control. All of rats challenged with 107 CFU S. typhimurium at fifth day. A faecal pellet was removed directly following its emission from each of the animals of a given cage. For each experiment, individual counts were made on one or two occasions for faeces from each of the animals of a given cage in order to establish possible individual variations.

Immediately following sampling, faeces were homogenised 10 times (W/V) in normal saline, then diluted in a decimal manner. S. typhimurium was counted by inoculation of dilutions on MacConkey agar medium with incubation for 2 days at 37°C. The numbers of salmonella per gram of feces of each rat were determined on 0, 1, 3, 5 and 7 days after challenging by pathogenic strain of S. typhimurium. Titers of anti-salmonella antibodies in rats sera were determined by agglutination tube test on 7, 14 and 21 days after challenge with salmonella.

Means of viable salmonella numbers excreted from feces and anti- salmonella antibodies titers compared with one-way ANOVA test among four groups of rats.

RESULTS AND DISCUSSION

The mortality rate of control rats (group D) that receiving normal saline and experimentally infected with S. typhimurium was 46.8% at first week after challenge. These animals showed signs of diarrhea and upon autopsy were found to have typhoid nodules in livers. S. typhimurium were found in the liver of these dead rats. In contrast, 5 days administration of S. boulardii prior to challenge with S.typhimurium resulted in 100% protection in three groups of rats (A, B and C). Mortality was significantly higher (p<0.05) in the control group (46.8%) when compared to the probiotic treated group (0%).

The means of Salmonella typhimurium numbers (expressed per gram of faeces) in four groups of rats after challenge were shown in Table 1.

S. typhimurium concentration increased rapidly over the first 1 day after challenge and then decreased gradually. The differences in the mean values among the treatment groups (A, B and C) are greater than would be expected by chance; there was a statistically significant difference (p<0.001). A decrease was apparent between days 5 and 7 and no live cells could be detected on fifth day in group A and seventh day in group B and C as well. Sixty six percent of rats in group A had no excretion of salmonella at all. Nevertheless some rats in group D excreted low bacteria after seventh day.

Table 1:
The means o f Salmonella typhimurium numbers (expressed per gram of feces ) in four groups of rats after challenge with S. typhimurium (A, B, C = Yeast treated and D = Control groups)

Table 2:
Geometrical Mean Titers (GMT) of anti-salmonella antibodies in sera of four groups of rats after challenge with S. typhimurium (A, B, C =Yeast treated, D = Control groups)

The Geometrical Mean Titers (GMT) of anti-salmonella antibodies in four groups of rats were shown in Table 2. The most titer was found in group A and less in group D.

Gastroenteritis in humans and animals is the main cause of acute diarrhea and is a frequent syndrome that can be due to several viral or bacterial pathogens or to parasites. Probiotics can be defined as nonpathogenic microorganisms that, when ingested, exert a positive influence on the health or physiology of the host. Recent studies showed that S. boulardii administration significantly reduced the frequency of diarrhoea in patients. In this study the preventive effect of Saccharomyces boulardii in rat was very marked. Comparing the total counts of salmonella in feces of rats after 24 h between the group A, B and C (Table 1) and D, differences of log 0.97, 0.8, 0.4 were detected (p<0.001). After 72 h, a lower level of colonization by salmonella in all experimental groups were found, which continued until the end of the experiment (96 h, Table 1). The most effective inhibition was found with administration of 106 yeast cells. Although there were no significant difference among experimental groups, it is not clear why this effect was decreased apparently with higher dose of yeast. Our experiments showed that administration of S. boulardii completely inhibited mortality. These findings suggest that this yeast has a preventive effect to reduce the levels of undesirable microbes such as salmonellae. In review literature, similar results to the application of the Saccahromyses boulardii were obtained in mice, hamster and tissue culture against C. difficile, Yersinia, Salmonella, E. coli and Shigella (Filho-Lima et al., 2000; Rodrigues et al., 1996). Several studies have documented that S. boulardii reduced the levels of C. difficile in hamster fecal pellets (Elmer and McFarland, 1987). Corthier et al. (1992) reported that 3.3x1010 S. boulardii ml in drinking water given to C. difficile infected mice, resulted in 85% protection.

The mechanisms of this inhibition are not known but antimicrobial substances production might be one possible mechanism of action of probiotics. Other effects of probiotics include competition for nutrients and receptors for adhesion to the host cell surface (Fuller, 1991).

Zbinden et al. (1999) reported that S. boulardii may have different modes of counteracting with bacterial enterotoxins. The yeast may have an intrinsic bactericidal activity, itself activating via metabolites or internal constituents. The absence of any effect seen in vitro would be against this hypothesis. The effect of yeasts might therefore rather be due to a change in one of the three successive stages in pathogenic capacity: adhesion, cytolytical effect and phagocytose

The effect of S. boulardii against Entamoeba histolytica trophozoites could also be explained by competition between yeast receptor sites and intestinal cells (Ravdin et al., 1985). One of the mechanisms by which S. boulardii exerts its immunoprotective effect in the gastrointestinal tract is a stimulation of the intestinal secretion of S-IgA and of the secretory component of immunoglobulins (Buts et al., 1990). We also found higher anti-salmonella antibodies titers in sera of rats that received S. boulardii before challenging with salmonella. However, there is a risk of fungaemia in immunocompromised patients and further large trials to document safety are needed before use of this agent will be accepted widely (Niault et al., 1999).

REFERENCES

  • Andreatti, F.R.L., E. Nepomuceno da Silva, A.R. Ribeiro, N. Kondo and P.R. Curi, 2000. Use of anaerobic cecal microflora, lactose and acetic acid for the protection of broiler chicks against experimental infection with Salmonella typhimurium and Salmonella entritidis. Braz. J. Microbiol., 31: 107-112.
    CrossRef    Direct Link    


  • Agawane, S.B. and P.S. Lonkar, 2004. Effect of probiotic containing Saccharomyces boulardii on experimental ochratoxicosis in broilers: Hematobiochemical studies. J. Vet. Sci., 5: 359-367.
    PubMed    Direct Link    


  • Buts, J.P., P. Bernasconi, J.P. Vaerman and C. Dive, 1990. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig. Dis. Sci., 35: 251-256.
    CrossRef    Direct Link    


  • Corthier, G., R. Lucas, S. Jouvert and F. Castex, 1992. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon, 30: 1583-1589.
    Direct Link    


  • Castagliuolo, I., M.F. Riegler, L. Valenick, J.T. LaMont and C. Pothoulakis, 1999. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect. Immun., 67: 302-307.
    Direct Link    


  • Elmer, G.W. and L.V. McFarland, 1987. Suppression by Saccharomyces boulardii of toxinogenic Clostridium difficile overgrowth after Vancomycin treatment in hamsters. Antimicrob. Agents Chemother., 31: 129-131.


  • Fuller, R., 1991. Probiotics in human medicine. Gut, 32: 439-442.
    Direct Link    


  • Filho-Lima, J.V., E.C. Vieira and J.R. Nicoli, 2000. Antagonistic effect of Lactobacillus acidophilus, Saccharomyces boulardii and Escherichia coli combinations against experimental infections with Shigella flexneri and Salmonella enteritidis subsp. typhimurium in gnotobiotic mice. J. Applied Microbiol., 88: 365-370.
    Direct Link    


  • Santos, Gil de los J.R., O.B. Storch and C. Gil-Turnes, 2005. Bacillus cereus var. toyoii and S. boulardii increased feed efficiency in broilers infected with Salmonella enteritidis. Br. Poult. Sci., 46: 494-497.
    Direct Link    


  • Laukova, A., P. Guba, R. Nemkova and M. Marekova, 2004. Inhibition of Salmonella enterica serovar Dusseldorf by enterocin A in gnotobiotic Japanese quails. Vet. Med. Czech, 49: 47-51.
    Direct Link    


  • McFarland, L.V. and P. Bernasconi, 1993. S. boulardii: A review of an innovative biotherapeutic agent. Microb. Ecol. Health Dis., 6: 157-171.
    Direct Link    


  • Niault, M., F. Thomas, J. Prost, F.H. Ansari and P. Kalfon, 1999. Fungaemia due to Saccharomyces species in a patient treated with enteral S. boulardii. Clin. Infect. Dis., 28: 930-930.


  • Ravdin, J.I., J.E. John, L. Johnston, D.J. Innes and R.L. Guerrant, 1985. Adherence of Entamoeba histolytica trophozoites to rat and human colonic mucosa. Infect. Immun., 48: 292-297.
    Direct Link    


  • Rodrigues, A.C.P., R.M. Nardi, E.A. Bambirra, E.C. Vieira and J.R. Nicoli, 1996. Effect of Saccharomyces boulardii against experimenttal oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J. Applied Bacteriol., 81: 251-256.
    Direct Link    


  • Roffe, C., 1996. Biotherapy for antibiotic-associated and other diarrheas. J. Infect., 32: 1-10.
    PubMed    Direct Link    


  • Zbinden, R., E.E. Gonczi and M. Altwegg, 1999. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb. Ecol. Health Dis., 11: 158-162.
    Direct Link    

  • © Science Alert. All Rights Reserved